MENOPAUSE SOCIETY CERTIFIED PRACTITIONER MSCP EXAM 2026/2027
300 VERIFIED QUESTIONS & ANSWERS THE MENOPAUSE SOCIETY
CERTIFICATION PREP 6 CORE DOMAINS INSTANT DOWNLOAD
96 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Differentiate the endocrinologic and physiologic changes of the menopausal transition and apply them to
risk stratification and diagnostic reasoning
2 Critically appraise and apply evidence from landmark trials (WHI, KEEPS, ELITE, SWAN, and
contemporary MHT trials) to individualize menopausal hormone therapy and non-hormonal management
3 Integrate multidisciplinary strategies for cardiovascular, skeletal, genitourinary, oncologic, and
neuropsychiatric health in the perimenopausal and postmenopausal patient
4 Menopause Society Certified Practitioner MSCP Exam 2026
5 2027 300 Verified Questions & Answers The Menopause Society Certification Prep 6 Core Domains
Instant Download
6 Foundations of Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains
7 Applied Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains
8 Advanced Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains
9 Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains Review
ABSTRACT
This study document brings together 96 carefully worded exam questions drawn from Menopause
Society Certified Practitioner MSCP Exam 2026/2027 300 Verified Questions & Answers The
Menopause Society Certification Prep 6 Core Domains Instant Download, with the strongest
emphasis placed on Differentiate the endocrinologic and physiologic changes of the menopausal
transition and apply them to risk stratification and diagnostic reasoning, Critically appraise and
apply evidence from landmark trials (WHI, KEEPS, ELITE, SWAN, and contemporary MHT trials)
to individualize menopausal hormone therapy and non-hormonal management, Integrate
multidisciplinary strategies for cardiovascular, skeletal, genitourinary, oncologic and and
neuropsychiatric health in the perimenopausal and postmenopausal patient. Every item follows the
wording style and level of reasoning you meet in the real paper, and each one is paired with a clear
rationale so the correct choice is never a guess. Work through the set at your own pace, mark the
questions that slow you down, then come back to them until the reasoning feels automatic.
Learners who revise this way walk into the exam room recognising the pattern behind the
questions instead of meeting them for the first time. Keep going - steady, honest practice is what
turns a difficult paper into a comfortable pass.
Page 1
,Q1 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A postmenopausal woman with a history of estrogen receptor-positive breast
cancer on tamoxifen presents with bothersome vasomotor symptoms. Which
pharmacologic option is most appropriate, and why?
A. Conjugated equine estrogens, because they are the most effective for vasomotor symptoms
B. Paroxetine, because it has minimal CYP2D6 inhibition and is preferred over fluoxetine in
tamoxifen users CORRECT
C. Fluoxetine, because it is the only SSRI with proven efficacy in tamoxifen users
D. Venlafaxine, because it is contraindicated with tamoxifen and should be avoided
RATIONALE: Paroxetine is a potent CYP2D6 inhibitor and can reduce conversion of tamoxifen to
its active metabolite endoxifen; thus it should be avoided, while desvenlafaxine, venlafaxine, or
low-dose escitalopram are preferred. Fluoxetine is also a strong CYP2D6 inhibitor and is not
preferred. Estrogen is generally contraindicated in breast cancer survivors unless risks/benefits
are carefully weighed, and tamoxifen does not contraindicate venlafaxine.
Q2 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A perimenopausal woman reports new-onset heavy, irregular menses and hot
flashes. Which statement best reflects the expected hormonal pattern of the late
menopausal transition?
A. Consistently elevated FSH with low estradiol and undetectable progesterone
B. Elevated FSH with variable estradiol that can be high, and progesterone deficiency due to
anovulation CORRECT
C. Low FSH with high estradiol due to enhanced negative feedback
D. Normal FSH and estradiol with isolated progesterone elevation
RATIONALE: The late menopausal transition is characterized by elevated FSH, erratic and often
high estradiol levels from follicular recruitment, and progesterone deficiency from anovulatory
cycles, which explains irregular bleeding. Consistently low estradiol and undetectable
progesterone describe the postmenopausal state. Low FSH with high estradiol is not typical, and
progesterone elevation is not characteristic.
Page 2
,Q3 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A postmenopausal woman on raloxifene for osteoporosis reports new
vulvovaginal dryness and dyspareunia. Which management is most appropriate?
A. Add systemic estrogen therapy to improve vaginal symptoms
B. Use a low-dose vaginal estrogen or DHEA, which is compatible with raloxifene and effectively
treats GSM CORRECT
C. Discontinue raloxifene and start an aromatase inhibitor
D. Prescribe a systemic progestin to counteract vaginal atrophy
RATIONALE: Raloxifene does not treat genitourinary syndrome of menopause (GSM); low-dose
vaginal estrogen or prasterone (DHEA) is effective and safe without significant systemic
absorption, so it does not negate raloxifene's skeletal benefits. Systemic estrogen is generally
avoided in women on SERMs for bone protection due to potential interaction and risk. Aromatase
inhibitors would worsen GSM, and progestins do not treat atrophy.
Q4 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
Which statement best captures the current evidence regarding the timing
hypothesis of menopausal hormone therapy and cardiovascular risk?
A. MHT increases cardiovascular risk regardless of age or time since menopause
B. MHT may reduce coronary heart disease risk when initiated within 10 years of menopause or
before age 60, with risk increasing with later initiation CORRECT
C. MHT has no effect on cardiovascular outcomes at any age
D. MHT reduces stroke risk when started after age 65
RATIONALE: The timing hypothesis, supported by WHI subgroup analyses and the ELITE trial,
suggests that MHT initiated within 10 years of menopause or before age 60 may be
cardioprotective or neutral, whereas initiation later is associated with increased CHD risk. MHT
does not reduce stroke risk at any age and is not uniformly harmful regardless of timing.
Page 3
, Q5 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A postmenopausal woman with bothersome vasomotor symptoms and a history of
migraine with aura is considering treatment. Which option is most appropriate?
A. Oral conjugated equine estrogens, because they are first-line for migraine with aura
B. Transdermal estradiol, because it avoids the hepatic first-pass effect and may be safer with
migraine with aura CORRECT
C. Ethinyl estradiol-containing combined hormonal contraceptive, because it stabilizes estrogen
levels
D. Progestin-only pill, because it is the only option for migraine with aura
RATIONALE: Migraine with aura is associated with increased ischemic stroke risk, and oral
estrogen may further increase thrombotic risk; transdermal estradiol avoids first-pass hepatic
effects and is preferred. Ethinyl estradiol is contraindicated in migraine with aura. Progestin-only
pills are not first-line for vasomotor symptoms, and oral CEE is not preferred over transdermal in
this context.
Q6 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
Which of the following best explains why the Women's Health Initiative (WHI)
findings on breast cancer risk with combined MHT require nuanced interpretation?
A. The WHI was a randomized trial with no confounding, so the risk is definitive
B. The WHI showed a small absolute increase in breast cancer risk with combined MHT, but the
risk was primarily in users with prior hormone exposure and the absolute risk was low
CORRECT
C. The WHI demonstrated that estrogen-alone therapy increases breast cancer risk similarly to
combined therapy
D. The WHI found that MHT reduces breast cancer risk when started early
RATIONALE: The WHI reported a small absolute increase in breast cancer risk with combined
estrogen-progestin therapy, but the absolute risk was low and the attributable risk was influenced
by prior hormone use and other factors. Estrogen-alone therapy did not show the same
increased risk. The WHI did not demonstrate a reduction in breast cancer risk with early initiation.
Page 4
300 VERIFIED QUESTIONS & ANSWERS THE MENOPAUSE SOCIETY
CERTIFICATION PREP 6 CORE DOMAINS INSTANT DOWNLOAD
96 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Differentiate the endocrinologic and physiologic changes of the menopausal transition and apply them to
risk stratification and diagnostic reasoning
2 Critically appraise and apply evidence from landmark trials (WHI, KEEPS, ELITE, SWAN, and
contemporary MHT trials) to individualize menopausal hormone therapy and non-hormonal management
3 Integrate multidisciplinary strategies for cardiovascular, skeletal, genitourinary, oncologic, and
neuropsychiatric health in the perimenopausal and postmenopausal patient
4 Menopause Society Certified Practitioner MSCP Exam 2026
5 2027 300 Verified Questions & Answers The Menopause Society Certification Prep 6 Core Domains
Instant Download
6 Foundations of Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains
7 Applied Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains
8 Advanced Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains
9 Menopause Medicine - Menopause Society Certified Practitioner (MSCP) Exam Domains Review
ABSTRACT
This study document brings together 96 carefully worded exam questions drawn from Menopause
Society Certified Practitioner MSCP Exam 2026/2027 300 Verified Questions & Answers The
Menopause Society Certification Prep 6 Core Domains Instant Download, with the strongest
emphasis placed on Differentiate the endocrinologic and physiologic changes of the menopausal
transition and apply them to risk stratification and diagnostic reasoning, Critically appraise and
apply evidence from landmark trials (WHI, KEEPS, ELITE, SWAN, and contemporary MHT trials)
to individualize menopausal hormone therapy and non-hormonal management, Integrate
multidisciplinary strategies for cardiovascular, skeletal, genitourinary, oncologic and and
neuropsychiatric health in the perimenopausal and postmenopausal patient. Every item follows the
wording style and level of reasoning you meet in the real paper, and each one is paired with a clear
rationale so the correct choice is never a guess. Work through the set at your own pace, mark the
questions that slow you down, then come back to them until the reasoning feels automatic.
Learners who revise this way walk into the exam room recognising the pattern behind the
questions instead of meeting them for the first time. Keep going - steady, honest practice is what
turns a difficult paper into a comfortable pass.
Page 1
,Q1 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A postmenopausal woman with a history of estrogen receptor-positive breast
cancer on tamoxifen presents with bothersome vasomotor symptoms. Which
pharmacologic option is most appropriate, and why?
A. Conjugated equine estrogens, because they are the most effective for vasomotor symptoms
B. Paroxetine, because it has minimal CYP2D6 inhibition and is preferred over fluoxetine in
tamoxifen users CORRECT
C. Fluoxetine, because it is the only SSRI with proven efficacy in tamoxifen users
D. Venlafaxine, because it is contraindicated with tamoxifen and should be avoided
RATIONALE: Paroxetine is a potent CYP2D6 inhibitor and can reduce conversion of tamoxifen to
its active metabolite endoxifen; thus it should be avoided, while desvenlafaxine, venlafaxine, or
low-dose escitalopram are preferred. Fluoxetine is also a strong CYP2D6 inhibitor and is not
preferred. Estrogen is generally contraindicated in breast cancer survivors unless risks/benefits
are carefully weighed, and tamoxifen does not contraindicate venlafaxine.
Q2 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A perimenopausal woman reports new-onset heavy, irregular menses and hot
flashes. Which statement best reflects the expected hormonal pattern of the late
menopausal transition?
A. Consistently elevated FSH with low estradiol and undetectable progesterone
B. Elevated FSH with variable estradiol that can be high, and progesterone deficiency due to
anovulation CORRECT
C. Low FSH with high estradiol due to enhanced negative feedback
D. Normal FSH and estradiol with isolated progesterone elevation
RATIONALE: The late menopausal transition is characterized by elevated FSH, erratic and often
high estradiol levels from follicular recruitment, and progesterone deficiency from anovulatory
cycles, which explains irregular bleeding. Consistently low estradiol and undetectable
progesterone describe the postmenopausal state. Low FSH with high estradiol is not typical, and
progesterone elevation is not characteristic.
Page 2
,Q3 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A postmenopausal woman on raloxifene for osteoporosis reports new
vulvovaginal dryness and dyspareunia. Which management is most appropriate?
A. Add systemic estrogen therapy to improve vaginal symptoms
B. Use a low-dose vaginal estrogen or DHEA, which is compatible with raloxifene and effectively
treats GSM CORRECT
C. Discontinue raloxifene and start an aromatase inhibitor
D. Prescribe a systemic progestin to counteract vaginal atrophy
RATIONALE: Raloxifene does not treat genitourinary syndrome of menopause (GSM); low-dose
vaginal estrogen or prasterone (DHEA) is effective and safe without significant systemic
absorption, so it does not negate raloxifene's skeletal benefits. Systemic estrogen is generally
avoided in women on SERMs for bone protection due to potential interaction and risk. Aromatase
inhibitors would worsen GSM, and progestins do not treat atrophy.
Q4 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
Which statement best captures the current evidence regarding the timing
hypothesis of menopausal hormone therapy and cardiovascular risk?
A. MHT increases cardiovascular risk regardless of age or time since menopause
B. MHT may reduce coronary heart disease risk when initiated within 10 years of menopause or
before age 60, with risk increasing with later initiation CORRECT
C. MHT has no effect on cardiovascular outcomes at any age
D. MHT reduces stroke risk when started after age 65
RATIONALE: The timing hypothesis, supported by WHI subgroup analyses and the ELITE trial,
suggests that MHT initiated within 10 years of menopause or before age 60 may be
cardioprotective or neutral, whereas initiation later is associated with increased CHD risk. MHT
does not reduce stroke risk at any age and is not uniformly harmful regardless of timing.
Page 3
, Q5 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
A postmenopausal woman with bothersome vasomotor symptoms and a history of
migraine with aura is considering treatment. Which option is most appropriate?
A. Oral conjugated equine estrogens, because they are first-line for migraine with aura
B. Transdermal estradiol, because it avoids the hepatic first-pass effect and may be safer with
migraine with aura CORRECT
C. Ethinyl estradiol-containing combined hormonal contraceptive, because it stabilizes estrogen
levels
D. Progestin-only pill, because it is the only option for migraine with aura
RATIONALE: Migraine with aura is associated with increased ischemic stroke risk, and oral
estrogen may further increase thrombotic risk; transdermal estradiol avoids first-pass hepatic
effects and is preferred. Ethinyl estradiol is contraindicated in migraine with aura. Progestin-only
pills are not first-line for vasomotor symptoms, and oral CEE is not preferred over transdermal in
this context.
Q6 DIFFERENTIATE THE ENDOCRINOLOGIC AND PHYSIOLOGIC CHANGES OF THE
MENOPAUSAL TRANSITION AND APPLY THEM TO RISK STRATIFICATION AND DIAGNOSTIC
REASONING
Which of the following best explains why the Women's Health Initiative (WHI)
findings on breast cancer risk with combined MHT require nuanced interpretation?
A. The WHI was a randomized trial with no confounding, so the risk is definitive
B. The WHI showed a small absolute increase in breast cancer risk with combined MHT, but the
risk was primarily in users with prior hormone exposure and the absolute risk was low
CORRECT
C. The WHI demonstrated that estrogen-alone therapy increases breast cancer risk similarly to
combined therapy
D. The WHI found that MHT reduces breast cancer risk when started early
RATIONALE: The WHI reported a small absolute increase in breast cancer risk with combined
estrogen-progestin therapy, but the absolute risk was low and the attributable risk was influenced
by prior hormone use and other factors. Estrogen-alone therapy did not show the same
increased risk. The WHI did not demonstrate a reduction in breast cancer risk with early initiation.
Page 4
